China’s NMPA approves InnoCare’s orelabrutinib to treat Marginal Zone Lymphoma
Orally available bruton’s tyrosine kinase (BTK) inhibitor, orelabrutinib irreversibly binds to BTK for inducing downstream kinase inactivation and cell death. It has been designed with a single ring